Zevra Therapeutics Inc Ordinary Shares ZVRA 深 滬
等待開盤 12-19 09:30:00 美东时间
8.10
-0.010
-0.12%
華盛通- 最 高8.315
- 今 開8.20
- 成交量 67.74万股
- 最 低 8.0501
- 昨 收 8.11
- 總市值 4.43亿
- 52周最高 13.16
- 市盈率 靜 --
- 換手率 1.24%
- 52周最低 6.19
- 委 比 32.05%
- 總股本 5467.96万
- 歷史最高 418.40
- 量 比 0.79
- 振 幅 3.27%
- 歷史最低 0.206
- 每 手 1
- 風險率 1.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zevra Therapeutics announces CFO transition
Zevra Therapeutics (NASDAQ:ZVRA) announced on Thursday that its CFO and Treasurer, R. LaDuane Clifton, will be stepping down from his position, effective December 31, 2025. The company has initiated ...
11-21 05:29
Zevra Therapeutics CFO R. LaDuane Clifto Departing, Effective Dec. 31
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financial Officer and
11-21 05:07
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Zevra Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results.
Zevra Therapeutics shares are trading lower after the company reported worse-th...
11-07 00:55
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
Zevra Therapeutics announced that its executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on November 12, 2025, at 11:30 a.m. ET. Management will also be available for one-on-one meetings with registered attendees. A live webcast link will be accessible via the company's Investor Relations website. Zevra focuses on developing therapies for rare diseases and will...
10-29 11:30
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics granted 38,000 stock options to two new employees under its 2023 Inducement Award Plan. The options vest over four years, with 25% vesting on the first anniversary and the remainder in three equal annual installments. The grants were approved by the Compensation Committee and align with Nasdaq Rule 5635(c)(4). Zevra focuses on developing therapies for rare diseases. For more information, visit www.zevra.com.
10-06 21:51
Zevra Therapeutics rises amid takeover speculation
Zevra Therapeutics gained 7.5% amid some takeover speculation. Collegium Pharmaceuticals (COLL) was looking at purchasing Zevra Therapeutics, though it couldn't get the financing for a potential deal,...
09-25 22:37
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.
09-25 18:11
